Shares of Beam Therapeutics Inc (NASDAQ:BEAM) have received an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.

Brokers have set a one year consensus target price of $31.75 for the company and are predicting that the company will post ($0.54) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Beam Therapeutics an industry rank of 51 out of 254 based on the ratings given to its competitors.

Several brokerages recently weighed in on BEAM. Wedbush restated an “outperform” rating on shares of Beam Therapeutics in a research note on Monday, March 2nd. ValuEngine upgraded Beam Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, April 1st.

Shares of BEAM traded down $1.56 during trading hours on Friday, hitting $24.95. The company had a trading volume of 336,948 shares, compared to its average volume of 360,922. Beam Therapeutics has a one year low of $13.00 and a one year high of $31.80. The business’s fifty day moving average price is $24.63.

Beam Therapeutics (NASDAQ:BEAM) last announced its earnings results on Tuesday, May 12th. The company reported ($1.03) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.48). The company had revenue of $0.01 million during the quarter. On average, research analysts forecast that Beam Therapeutics will post -2.59 earnings per share for the current fiscal year.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. It is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders.

Recommended Story: What are benefits of a growth and income fund?

Get a free copy of the Zacks research report on Beam Therapeutics (BEAM)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with's FREE daily email newsletter.